Trial Profile
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Pharmacodynamics
- Acronyms TRANSLATE
- 11 Jan 2018 Status changed from recruiting to completed.
- 28 Oct 2015 New trial record